

Singular Health Group Ltd: SHG

# ASX Announcement

21 May 2024

## Vesting of Performance Rights and Cleansing Statement

**21 May 2024** – Medical technology company Singular Health Group Ltd (ASX: SHG) ("Singular Health", or "the Company") advises that, in accordance with the terms of the Company's Employee Incentive Plan ("Plan"), 250,000 Performance Rights ("Performance Rights") that were issued to Singular Health group employees have vested due to achievement of the respective performance conditions and KPI's.

Upon vesting, 250,000 Performance Rights have been exercised and the Company has issued the equivalent number of fully paid ordinary shares ("Shares") in accordance with the terms of the Plan. An Appendix 2A applying for quotation of the Shares will be released immediately following this announcement.

The Shares have been issued under Exception 9 of ASX Listing Rule 7.1 and 7.1A and have not utilised the Company's existing placement capacity under the Listing Rules.

## Notice pursuant to Section 708A(5)(e) of the Corporations Act 2001

The Company gives notice pursuant to section 708A(5)(e) of the Corporations Act 2001 (Cth) ("**Corporations Act**") that:

1. the Company on 21 May 2024 issued 250,000 Shares without disclosure to investors under Part 6D.2 of the Corporations Act;
2. the Company is providing this notice under section 708A(5)(e) of the Corporations Act;
3. as at the date of this notice, the Company has complied with:
  - a. the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
  - b. sections 674 and 674A of the Corporations Act; and
4. as at the date of this notice, there is no "excluded information" within the meaning of sections 708A(7) and 708A(8) of the Corporations Act which is required to be disclosed by the Company.

This announcement is authorised for release by the Board of Directors of the Company.

**Ends**

For further information contact

Investors	Corporate
James Hill +61 413 825 646 jhill@singular.health	Steven Wood Company Secretary support@singular.health

**About Singular Health:**

Singular Health Group Limited (ASX: SHG) is a medical technology company utilising advanced technologies to develop patient-specific solutions.

Singular Health's 3Dicom software solutions empower patients and practitioners to better visualise, communicate, and understand medical imaging data. 3Dicom MD® is cleared for diagnostic use in the United States.

Singular 3DP, a wholly owned subsidiary of Singular Health, uses advanced manufacturing including 3D printing and post-processing to manufacture TGA-approved patient-specific medical devices.

To learn more, visit: <https://www.singular.health> and <https://investors.singular.health/>